Prediction of Very Short Survival in Patients with Brain Metastases from Breast Cancer

Clinical Oncology

Volumn 20, Issue 5, 2008, Pages 337-339

  Nieder, C ^a,b   Marienhagen, K ^c   Thamm, R ^d   Astner, S T ^d   Molls, M ^d   Norum, J ^b,c  

^a Radiation Oncology Unit   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Brain metastases; breast cancer; prognosis; radiotherapy; whole brain radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; DEXAMETHASONE;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; FUNCTIONAL ASSESSMENT; GERMANY; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; METASTASIS; NORWAY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL TIME; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; GERMANY; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; NORWAY; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 43149125168     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2008.03.005     Document Type: Article

References (11)

1. Lock M., Chow E., Pond G.R., et al. Prognostic factors in brain metastases: can we determine patients who do not benefit from whole-brain radiotherapy?. Clin Oncol (R Coll Radiol) 16 (2004) 332-338
2. Andrews D.W., Scott C.B., Sperduto P.W., et al. Whole brain radiation therapy with and without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomized trial. Lancet 363 (2004) 1665-1672
3. Mehta M.P., Rodrigus P., Terhaard C.H., et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21 (2003) 2529-2536
4. Khuntia D., Brown P., Li J., and Mehta M.P. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 24 (2006) 1295-1304
5. Gaspar L., Scott C., Rotman M., et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37 (1997) 745-751
6. Nieder C., Nestle U., Motaref B., Walter K., Niewald M., and Schnabel K. Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes?. Int J Radiat Oncol Biol Phys 46 (2000) 297-302
7. Mahmoud-Ahmed A.S., Suh J.H., Lee S.Y., Crownover R.L., and Barnett G.H. Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study. Int J Radiat Oncol Biol Phys 54 (2002) 810-817
8. Bartsch R., Fromm S., Rudas M., et al. Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer - a retrospective analysis. Radiother Oncol 80 (2006) 313-317
9. Le Scodan R., Massard C., Mouret-Fourme E., et al. Brain metastases from breast carcinoma: validation of the Radiation Therapy Oncology Group recursive partitioning analysis classification and proposition of a new prognostic score. Int J Radiat Oncol Biol Phys 69 (2007) 839-845
10. Claude L., Perol D., Ray-Coquard I., et al. Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma. Radiother Oncol 76 (2005) 334-339
11. Priestman T.J., Dunn J., Brada M., et al. Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin Oncol (R Coll Radiol) 8 (1996) 308-315